The review also calls for future clinical trials to include detailed dietary assessments to better understand long-term health effects
Molestias digestivas (las ms comunes) Nuseas: entre 20% y 44% de los pacientes (ms comn al inicio y con dosis altas) Vmitos: entre 10% y 24% Diarrea: entre 12% y 30% Estreimiento: entre 6% y 24% , segn la molcula y la duracin En general, 4 a 7 de cada 10 pacientes (40-70%) presentan algn sntoma digestivo durante el tratamiento, sobre todo en las primeras semanas, con tendencia a mejorar con el tiempo (1,8-11)
Wei J, Hanna T, Suda N, Karsenty G, Ducy P
It stimulates a process called lipolysis, which is the breakdown of fat stored in the body
The starting dosage is 0.25mg, which is gradually over 4 months until the maximum or full dosage of 2.4mg is attained